A comprehensive assessment of the bioengineered wound care technologies and products for advanced wound management, this report provides a detailed analysis of twenty-two next-generation wound care products, including tissue-engineered skin substitutes, synthetic and harvested regeneration matrices, autologous grafts and biologically active cellular therapies. Management of chronic wounds and ulcers remains one of the most costly unsolved healthcare challenges. The report profiles companies active in bioengineered wound care therapeutics, and evaluates technology and business risk factors and market issues. This is a market that is experiencing unabated growth, as the aging of populations in developed countries leads to increasing caseloads of chronic wounds due to disease and immobility. With conditions such as diabetes, a major cause of skin ulcers, forecast to grow worldwide during the next fifteen years, demand for advanced wound care products and therapies will flourish. The report provides an easy-to-understand assessment of bioengineered wound care and the impact it will have on the advanced wound management segment of the healthcare industry.

Publication Date: February 2007